Meta-analysis: slightly increased cancer risk with psoriasis

  • Vaengebjerg S & al.
  • JAMA Dermatol
  • 19 Feb 2020

  • curated by Brian Richardson, PhD
  • Clinical Essentials
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Psoriasis is associated with increased risk for several cancer types, according to a systematic review and meta-analysis.

Why this matters

  • This meta-analysis supports a previously reported link between psoriasis and cancer risk while clarifying the contributions of psoriatic arthritis and biologic therapies.

Key results

  • Patients with psoriasis had overall cancer prevalence of 4.78%.
    • Risk ratio (RR), 1.21 (95% CI, 1.11-1.33).
  • Risk (RR; 95% CI) was increased for:
    • Keratinocyte cancer: 2.28 (1.73-3.01).
    • Lymphomas: 1.56 (1.37-1.78).
    • Lung cancer: 1.26 (1.13-1.40).
    • Bladder cancer: 1.12 (1.04-1.19).
  • Cancer risk was not increased in patients with psoriasis treated with biologic agents (RR, 0.97; 95% CI, 0.85-1.10) or with psoriatic arthritis (RR, 1.02; 95% CI, 0.97-1.08).

Study design

  • 112 studies with 2,053,932 total patients were included in the meta-analysis.
  • Funding: None disclosed.

Limitations

  • Heterogeneity between included studies.